Dr. Guttuso To Study Anti-Seizure Medication in Morning Sickness in NIH-Funded TrialPosted: June 19, 2014
Thomas Guttuso Jr,, MD, Associate Professor of Neurology, is continuing his work studying gabapentin in countering morning sickness or hyperemesis gravidarum associated with earlier stages of pregnancy. He will be conducting the first randomized, double-blinded study of the commonly used anti-seizure agent in a clinical trial supported by a $1.3 million grant from the National Institutes of Health. Dr. Guttuso is the Principal Investigator on the award. In prior pilot work published in 2010, Dr. Guttuso, who also holds an appointment in the UB Dept. of Obstetrics and Gynecology, showed that gabapentin, a relatively safe agent with essentially no drug-drug interactions or risk of congenital birth defects, reduced nausea and vomiting in women suffering from hyperemesis gravidarum by 80-95 percent. For more information see http://www.buffalo.edu/news/releases/2014/06/025.html.